Apel­lis shares tum­ble on re­ports of eye in­flam­ma­tion in pa­tients tak­ing Syfovre

Apel­lis Phar­ma­ceu­ti­cals took a 21% hit to its stock price $APLS on Mon­day morn­ing, wip­ing $2 bil­lion from its mar­ket cap af­ter a group of reti­nal physi­cians warned its mem­bers about po­ten­tial safe­ty is­sues with the com­pa­ny’s ge­o­graph­ic at­ro­phy treat­ment Syfovre.

The Amer­i­can So­ci­ety of Reti­na Spe­cial­ists (ASRS) is­sued the warn­ing on Sat­ur­day, say­ing it’s re­ceiv­ing re­ports from physi­cians about in­traoc­u­lar in­flam­ma­tion in pa­tients who re­ceived the in­jec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER